Free Trial
NASDAQ:QTTB

Q32 Bio (QTTB) Stock Price, News & Analysis

Q32 Bio logo
$2.14 0.00 (0.00%)
As of 03:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Q32 Bio Stock (NASDAQ:QTTB)

Key Stats

Today's Range
$2.08
$2.24
50-Day Range
$1.84
$3.52
52-Week Range
$1.80
$53.79
Volume
81,454 shs
Average Volume
174,102 shs
Market Capitalization
$26.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.71
Consensus Rating
Hold

Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Remove Ads

Q32 Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

QTTB MarketRank™: 

Q32 Bio scored higher than 51% of companies evaluated by MarketBeat, and ranked 511th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Q32 Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Q32 Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Q32 Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Q32 Bio are expected to grow in the coming year, from ($12.32) to ($3.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Q32 Bio is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Q32 Bio is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Q32 Bio has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Q32 Bio's valuation and earnings.
  • Percentage of Shares Shorted

    23.36% of the float of Q32 Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Q32 Bio has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Q32 Bio has recently decreased by 21.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Q32 Bio does not currently pay a dividend.

  • Dividend Growth

    Q32 Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.36% of the float of Q32 Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Q32 Bio has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Q32 Bio has recently decreased by 21.37%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Q32 Bio has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Q32 Bio this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for QTTB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Q32 Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.32% of the stock of Q32 Bio is held by institutions.

  • Read more about Q32 Bio's insider trading history.
Receive QTTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter.

QTTB Stock News Headlines

Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
Q32 Bio price target lowered to $15 from $16 at Wells Fargo
Q32 Bio: Q4 Earnings Snapshot
Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart
See More Headlines

QTTB Stock Analysis - Frequently Asked Questions

Q32 Bio's stock was trading at $3.44 at the beginning of the year. Since then, QTTB shares have decreased by 37.8% and is now trading at $2.14.
View the best growth stocks for 2025 here
.

Q32 Bio Inc. (NASDAQ:QTTB) released its quarterly earnings data on Tuesday, March, 11th. The company reported ($1.16) earnings per share for the quarter, topping analysts' consensus estimates of ($1.25) by $0.09.

Top institutional shareholders of Q32 Bio include Acorn Capital Advisors LLC (6.60%), Monaco Asset Management SAM (4.72%), Sanofi (2.00%) and Trustees of Columbia University in the City of New York (1.10%).
View institutional ownership trends
.

Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
3/11/2025
Today
3/19/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:QTTB
Previous Symbol
NASDAQ:QTTB
Fax
N/A
Employees
39
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.71
High Stock Price Target
$100.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+1,059.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-112,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$-6,651,000.00
Price / Cash Flow
N/A
Book Value
$22.47 per share
Price / Book
0.09

Miscellaneous

Free Float
10,220,000
Market Cap
$25.99 million
Optionable
N/A
Beta
-0.27
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:QTTB) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners